Fast Five Quiz: Metastatic Melanoma Treatment

Winston W. Tan, MD, FACP


May 24, 2023

KIT mutations, like BRAF mutations, have the potential to change over the course of disease progression. Compared with patients without these mutations, patients with metastatic melanoma and activating mutations in KIT are more likely to respond to tyrosine kinase inhibitor imatinib. However, NCCN guidelines specify that imatinib is not a preferred agent but may be useful for those who are ineligible or unresponsive to other more effective therapeutic options. Current data suggest that at this time, c-Kit mutant patients should be treated with ICIs at first line, and only after the failure of these regimens, c-Kit inhibitors should be considered.

Learn more about the treatment of advanced-stage melanoma with KIT mutations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.